CN116075298B - 用于治疗冠状病毒感染的方法 - Google Patents

用于治疗冠状病毒感染的方法

Info

Publication number
CN116075298B
CN116075298B CN202180037562.1A CN202180037562A CN116075298B CN 116075298 B CN116075298 B CN 116075298B CN 202180037562 A CN202180037562 A CN 202180037562A CN 116075298 B CN116075298 B CN 116075298B
Authority
CN
China
Prior art keywords
cov
sars
compound
subject
probenecid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180037562.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN116075298A (zh
Inventor
拉尔夫·A·特尔普
杰克琳·默里
罗伯特·杰夫·霍根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia Research Foundation Inc
Original Assignee
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/875,487 external-priority patent/US11116737B1/en
Application filed by University of Georgia Research Foundation Inc filed Critical University of Georgia Research Foundation Inc
Publication of CN116075298A publication Critical patent/CN116075298A/zh
Application granted granted Critical
Publication of CN116075298B publication Critical patent/CN116075298B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180037562.1A 2020-04-10 2021-04-09 用于治疗冠状病毒感染的方法 Active CN116075298B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063008624P 2020-04-10 2020-04-10
US63/008,624 2020-04-10
US202063023021P 2020-05-11 2020-05-11
US63/023,021 2020-05-11
US16/875,487 2020-05-15
US16/875,487 US11116737B1 (en) 2020-04-10 2020-05-15 Methods of using probenecid for treatment of coronavirus infections
EP20202059.0 2020-10-15
EP20202059.0A EP3892269B1 (en) 2020-04-10 2020-10-15 Probenecid for treating coronavirus infections
US202163151551P 2021-02-19 2021-02-19
US63/151,551 2021-02-19
PCT/US2021/026588 WO2021207606A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Publications (2)

Publication Number Publication Date
CN116075298A CN116075298A (zh) 2023-05-05
CN116075298B true CN116075298B (zh) 2026-03-20

Family

ID=78023981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037562.1A Active CN116075298B (zh) 2020-04-10 2021-04-09 用于治疗冠状病毒感染的方法

Country Status (5)

Country Link
EP (1) EP4132503B1 (https=)
JP (1) JP7840570B2 (https=)
CN (1) CN116075298B (https=)
AU (1) AU2021254262A1 (https=)
WO (1) WO2021207606A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4157288A2 (en) * 2020-06-02 2023-04-05 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
JP2024529291A (ja) * 2021-07-06 2024-08-06 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ウイルス感染症の処置および予防のための組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20130280806A1 (en) * 2010-05-17 2013-10-24 Donald Rubin Mammalian genes involved in infection
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
CN111601618A (zh) * 2018-09-14 2020-08-28 江阴贝瑞森制药有限公司 孟鲁司特与肽的新缀合物
EA202193251A1 (ru) * 2019-06-05 2022-03-10 Эмори Юниверсити Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Consideration of Pannexin 1 channels in COVID-19 pathology and treatment;Leigh Anne Swayne等;《Am J Physiol Lung Cell Mol Physiol》;20200610;第319卷(第1期);L121-L125 *
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression;Sanju Sinha等;《Mol Syst Biol》;20200729;第16卷(第7期);1-9 *
Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro;Jackelyn Murray等;《Scientific Reports》;20210910;第11卷;1-7 *

Also Published As

Publication number Publication date
EP4132503A4 (en) 2024-02-14
EP4132503A1 (en) 2023-02-15
JP7840570B2 (ja) 2026-04-06
WO2021207606A1 (en) 2021-10-14
CA3173187A1 (en) 2021-10-14
CN116075298A (zh) 2023-05-05
EP4132503B1 (en) 2026-04-22
AU2021254262A1 (en) 2022-11-03
JP2023520929A (ja) 2023-05-22

Similar Documents

Publication Publication Date Title
US11903916B2 (en) Methods of using probenecid for treatment of coronavirus infections
Chen et al. Overview of lethal human coronaviruses
EP1526175B1 (en) Coronavirus, nucleic acid, protein and methods for the generation of vaccine, medicaments and diagnostics
Zehra et al. Corona virus versus existence of human on the earth: A computational and biophysical approach
CA2523875A1 (en) Sars virus nucleotide and amino acid sequences and uses thereof
CN116075298B (zh) 用于治疗冠状病毒感染的方法
Kooshkaki et al. Coronavirus disease 2019: a brief review of the clinical manifestations and pathogenesis to the novel management approaches and treatments
TW200530271A (en) Receptor binding polypeptides
Hanh et al. Evidence for asthma in the lungs of mice inoculated with different doses of Toxocara canis
Budholiya et al. COVID-19: a global pandemic of 21st Century
CN100588708C (zh) 抗sars疫苗
CN1237184C (zh) 抗SARS－CoV药物作用靶标、药物筛选方法及抗SARS药物
WO2022221920A1 (en) Novel compositions and methods for treating coronavirus infections
CN117677631A (zh) 用于治疗冠状病毒感染的新型组合物和方法
Waris et al. A comprehensive study of sars-cov-2: From 2019-ncov to covid-19 outbreak
CA3173187C (en) Methods for treatment of coronavirus infections
Akshay et al. Severe Acute Respiratory Syndrome associated Corona Virus [SARS-CoV]
Javed et al. Morphology, Pathogenesis, Genome Organization, and Replication of Coronavirus (COVID-19)
CN100429321C (zh) Sars冠状病毒orf8区域的应用
Bisimwa SARS-CoV-2: pathogenesis, evolution and ongoing efforts in drug and vaccine development
Shah et al. The Emergent Pandemic-A Review on Coronavirus SARS-Cov-2: Virology, Pathogenesis and Outbreak
Mandan et al. PANDEMIC IN INDIA OF COVID 19 AND COMMUNITY TRANSMISSION RC PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH, SHIRPUR, MAHARASHTRA
WO2005001096A1 (en) Vaccines against sars
Dheemant et al. Unveiling the dermatological manifestations of nCOVID-19
Dar et al. An Overview of Novel Coronavirus Disease 2019: A Global Havoc

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant